WELCOME

ACHIEVING IMPACT:
Charting the Course to Meet the Challenges Ahead

Distinguished guests, colleagues, and partners from across the globe, on behalf of the Coalition against Typhoid, housed at the Sabin Vaccine Institute, it is our great pleasure to welcome you to the 12th International Conference on Typhoid & Other Invasive Salmonelloses. For the first time in conference history, for the next three days, we will convene more than 450 researchers, policy makers, immunization managers and advocates from across 46 countries through a full-scale virtual event.

We would like to extend our deepest gratitude to the Bill & Melinda Gates Foundation, Bharat Biotech, IDL Biotech, and the Typhoid Vaccine Acceleration Consortium for their generous support of this much needed convening. Over the next three days, we will share and discuss research findings, exchange ideas, and identify the best strategies to reduce the burden of typhoid, paratyphoid and invasive nontyphoidal Salmonella disease for communities around the world. The wonderful thing about this conference is the international perspective you each bring to these discussions. This year’s conference theme, “Achieving Impact: Charting the Course to Meet the Challenges Ahead,” reflects our shared commitment to navigating complexity on the road to transformational progress.

The novel coronavirus, SARS-CoV-2, has disrupted lives worldwide on an unprecedented scale. Indeed, the pandemic exacerbated existing economic, social and health disparities, and introduced new barriers and challenges in conducting our research particularly as it relates to the tremendous advancements made pre-pandemic on enteric fever control.

Though the pandemic may have disrupted our work, it has not thrown us off course. To the contrary, it has made us even more resolute. A lot has happened since we last convened in 2019. In November 2019, we witnessed Pakistan become the first country to introduce TCV into the national routine immunization program. We’ve also celebrated Liberia and Zimbabwe becoming the first and second African countries to introduce TCV, and most recently, introduction in Samoa in the Western Pacific region in August 2021. To date, nearly 30 million children have been vaccinated, and progress continues to be made every day as plans to introduce TCV in Malawi and Nepal are underway.

We are applying lessons learned and using them as fuel to propel us into the next generation of research and activities in Enteric Fever control. We are turning a corner, adapting to our environment and continuing to fuel collaboration across geographic borders through the creative utilization of modern technology. There is a huge global spotlight on health right now, which we have an opportunity to leverage. COVID-19 will not be the last obstacle we face, but despite that, we will prepare and prevail together. We thank you for joining us as we take bold and innovative steps in achieving impact through charting the course to meet the challenges ahead.

Sincerely,

Denise Garrett, MD, MSc
Vice President, Applied Epidemiology
Sabin Vaccine Institute
Director, Coalition against Typhoid

Amy Finan
Chief Executive Officer
Sabin Vaccine Institute

Garrett
Finan